Multiple myeloma: Anti-BCMA BiTE AMG 701 shows preclinical promise

Bookmark and Share
Published: 8 Dec 2019
Views: 959
Dr Yu-Tzu Tai - Dana-Farber Cancer Institute, Boston, USA

Dr Yu-Tzu Tai speaks to ecancer at the ASH 2019 meeting in Orlando about updated results from a study evaluating the anti-BCMA bispecific T-cell engager (BiTE) AMG 701 for multiple myeloma.

She reports that AMG 701 can potently induce myeloma cell lysis in sensitive and resistant cells.

Dr Tai also details that they found that AMG 701 significantly induces CD4 and CD8 T cell proliferation and activation.

ecancer's filming has been kindly supported by Amgen through the ecancer Global Foundation. ecancer is editorially independent and there is no influence over content.

Read more about the study here